Document Detail


Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization.
MedLine Citation:
PMID:  10385787     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Coronary dissections and intracoronary thrombosis are the most important determinants of acute and subacute complications occurring during coronary interventions. Stents have proved efficacious to repair coronary dissections. The formation of intracoronary thrombi during percutaneous coronary intervention (PCI), the other main pathogenic mechanism for acute complications of PCI, has also been implicated in the pathogenesis of long-term ischemic outcomes. To reduce intracoronary thrombosis, all PCIs have been historically performed during intense short-term anticoagulation with the combination of unfractionated heparin plus aspirin. Compelling data on the central role of platelets in arterial thrombosis have made apparent the need for more potent antiplatelet agents for the treatment of patients undergoing PCI.
Authors:
G Dangas; A Colombo
Related Documents :
24958077 - The pathophysiology of heart failure with preserved ejection fraction.
24131787 - Impact of cardiac support device combined with slow-release prostacyclin agonist in a c...
24035047 - Cardiac risk factors and risk scores vs cardiac computed tomography angiography: a pros...
23928367 - Bifid cardiac apex in a 25-year-old male with sudden cardiac death.
3768217 - Value of the bipolar lead cm5 in electrocardiography.
16494287 - Identifying and managing acute coronary syndrome.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American heart journal     Volume:  138     ISSN:  0002-8703     ISO Abbreviation:  Am. Heart J.     Publication Date:  1999 Jul 
Date Detail:
Created Date:  1999-07-26     Completed Date:  1999-07-26     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S16-23     Citation Subset:  AIM; IM    
Affiliation:
Cardiology Research Foundation, the Centro Cuore Columbus, Milano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Balloon, Coronary / adverse effects*
Antibodies, Monoclonal / therapeutic use
Clinical Trials as Topic
Coronary Thrombosis / blood,  prevention & control*
Forecasting
Humans
Immunoglobulin Fab Fragments / therapeutic use
Myocardial Infarction / therapy
Peptides / therapeutic use
Platelet Aggregation Inhibitors / therapeutic use*
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
Stents / adverse effects
Tyrosine / analogs & derivatives,  therapeutic use
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Peptides; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/eptifibatide; 144494-65-5/tirofiban; 55520-40-6/Tyrosine; X85G7936GV/abciximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials.
Next Document:  Economic issues in glycoprotein IIb/IIIa receptor therapy.